The Trump administration announced a policy on January 22, 2026, prohibiting the use of fetal tissue from elective abortions in federally funded research. The National Institutes of Health (NIH) confirmed that funds will cease supporting research involving human fetal tissue from elective abortions across both its Intramural Research Program and extramural grants. NIH Director Jay Bhattacharya stated the decision aims to advance science by investing in breakthrough technologies that model human health and disease. The announcement noted a steady decline in NIH-supported research using human fetal tissue, with only 77 projects funded in Fiscal Year 2024. The policy shift encourages the use of alternatives like organoids, tissue chips, and computational biology, which are cited as robust platforms that reduce ethical concerns.
about 1 month ago
The Trump administration announced on January 22, 2026, that the National Institutes of Health (NIH) will no longer fund research using human fetal tissue from elective abortions.1 2 3
This policy applies to all NIH intramural and extramural research, including grants and contracts.1
The U.S. Department of Health and Human Services (HHS) confirmed the halt, emphasizing consistent application across the department.3
NIH Director Jay Bhattacharya stated the shift invests in advanced technologies like organoids, tissue chips, and computational biology to model human health and disease.1 2
He noted taxpayer-funded research must align with current science and American values.1 3
HHS Secretary Robert F. Kennedy Jr. highlighted both ethical demands and scientific superiority of alternatives.3
Fetal tissue research has been federally funded for decades under both parties, aiding HIV and cancer studies, but usage declined since 2019 to 77 projects in FY2024.1 2
The first Trump term restricted its use on NIH campuses and added hurdles for external researchers, later reversed by Biden.2
Existing cell lines from fetal tissue remain permissible.2
Father Tadeusz Pacholczyk of the National Catholic Bioethics Center praised the move as ethically sound, addressing past abuses and linking funding to good science.3
The announcement precedes the 53rd March for Life on January 23.1
The Small Business Administration is reviewing $88 million in COVID-era loans to Planned Parenthood.1
The State Department plans to expand the Mexico City policy barring overseas taxpayer-funded abortions.1
NIH will seek public comment on reducing reliance on human embryonic stem cells.1 2 3
Pro-life groups argue alternatives suffice, but some scientists contend substitutes are not always adequate for critical research.2
Prohibit NIH fetal‑tissue research, favoring alternative human‑cell models
The proposal to prohibit National Institutes of Health (NIH) funding for fetal-tissue research, while promoting alternative human-cell models, resonates deeply with the Catholic Church's unwavering defense of human life from conception. Church documents consistently condemn any scientific endeavor that relies on the destruction of innocent human life, particularly through abortion or embryonic experimentation, as gravely immoral. Instead, they endorse ethical research paths, such as adult stem cells or tissues superfluous to fetal development, emphasizing the dignity of every human person created in God's image. This analysis draws from papal encyclicals, moral theological reflections, and bioethical directives to evaluate the proposal's alignment with Catholic principles.
Fetal tissue research, as historically practiced and funded by entities like the NIH, is inextricably linked to elective abortions, rendering it ethically untenable. Significant U.S. government funding—over $500 million historically, with more than $100 million in 2019 alone—has supported projects using tissues harvested from aborted children, often through collaborations with abortion providers like Planned Parenthood. These practices trace back decades: in the 1970s, experimentation on live aborted fetuses was acknowledged post-Roe v. Wade; by 2000, allegations of illegal fetal tissue sales prompted federal investigations; and 2015 undercover videos revealed ongoing procurement.
Pope John Paul II explicitly denounces such exploitation in Evangelium Vitae, affirming that "the direct and voluntary killing of an innocent human being is always gravely immoral." This extends to biomedical applications: "the use of human embryos or fetuses as an object of experimentation constitutes a crime against their dignity as human beings." Even if intended to benefit others, procedures exploiting aborted fetuses or embryos—produced via in vitro fertilization or otherwise—are "absolutely unacceptable." Fr. Ezra Sullivan, O.P., underscores that cell lines like WI-38 (from a 1962 aborted girl) and HEK-293 originated from induced abortions, not miscarriages, and continue to fuel demands for fresh tissue. Harvesting often occurs from still-living children, violating the inviolable right to life established "from the first instant" of fertilization.
Catholic teaching rejects any justification, even humanitarian ones: "No evil can be excused because it is done with a good intention," as St. Thomas Aquinas teaches, echoed in papal condemnations of abortion "willed as an end or as a means." Thus, NIH funding perpetuates a cycle where science profits from grave moral disorder.
Beyond direct immorality, using abortion-derived tissues risks scandal and incentivizes further killings. Sullivan warns that demand for fetal parts "could not help but create an increased inducement" for abortions, potentially doubling abortion industry revenue without explicit payment. Parents may even seek abortions believing "medical use" of their child's tissue is possible, as studies confirm. Claims that established cell lines eliminate new abortions are contradicted by ongoing practices, including 2015 Chinese research harvesting fresh tissue for economic and scientific necessity.
Pope John Paul II highlights the spiritual dimension of the human person, transcending mere biology: the mind's mystery points to a soul-imaged relationship with God (Gen 1:26-27; 2:7). Reducing persons to "biological material" profanes this dignity. The U.S. Conference of Catholic Bishops permits only post-mortem organ donation "for ethically legitimate purposes," excluding tissues from illicit abortions. Prohibiting NIH research would mitigate scandal, aligning with the Church's call to reject procedures that "disregard the inviolable dignity of the human being."
The Church actively promotes morally licit alternatives, favoring research that respects life. John Paul II encouraged "research on adult human tissue or tissue superfluous to normal fetal development," explicitly rejecting embryonic sources as "logically and morally contradictory." He praised initiatives like the Paul VI Institute for ethical fertility and infertility studies, urging "more and more effective solutions... in conformity with the sexual and procreative ethics" of the Magisterium.
Criteria for licit donation include: no harm to the donor's life or identity; free consent; and no link to grave evils like abortion. Adult stem cells and non-embryonic models fulfill these, offering hope without complicity. Prenatal diagnostics are licit only if avoiding eugenic abortions aimed at "normality." Catholic health care must champion conscientious objection to abortion-related practices, affirming life's sacredness per the Hippocratic tradition. Favoring alternatives thus advances science while serving the "Gospel of life."
This proposal counters a culture where "science and the practice of medicine risk losing sight of their inherent ethical dimension," tempting professionals to become "manipulators of life." The International Theological Commission stresses theology's integration of scientific methods under truth's unity, welcoming dialogue but rejecting isolation from moral critique. By prohibiting illicit research, society upholds Evangelium Vitae's vision: respecting the "unformed substance" beheld by God (Ps 139:16).
In summary, Catholic sources unequivocally support prohibiting NIH fetal-tissue research due to its roots in abortion and risks of further harm, while endorsing ethical human-cell alternatives as faithful to human dignity and Church teaching. This path fosters true progress, honoring life's sanctity from conception to natural death.